Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Breast Neoplasms
Interventions
DRUG

TS-1 and Eloxatin

"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week~Number of Cycles: until progression or unacceptable toxicity"

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Korean Cancer Study Group

OTHER

collaborator

National Cancer Center, Korea

OTHER_GOV

collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Asan Medical Center

OTHER

collaborator

Severance Hospital

OTHER

lead

Seoul National University Hospital

OTHER